---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-071467"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:44:06.933885+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cytek Biosciences appoints William McCombe as CFO, reaffirms 2024 revenue guidance

## Summary
- Patrik Jeanmonod steps down as CFO to become Head of Corporate Development Analytics, effective March 17, 2024.
- William McCombe appointed CFO effective March 18, 2024; base salary $420,000, target bonus 50%, equity grant $1.25M.
- McCombe previously CFO at Velo3D, HZO, and Maxar Technologies; over 20 years investment banking experience.
- Cytek reaffirms 2024 revenue guidance of $203M-$213M (5-10% growth) and expectation of positive net income.
- No disagreement cited for Jeanmonod's transition; company reiterates 2024 outlook unchanged.

## SEC filing metadata
- accession: 0001193125-24-071467
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312524071467/0001193125-24-071467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312524071467/d773908d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-071467
- JSON: https://secwatch.observer/filing/0001193125-24-071467.json
- Plain text: https://secwatch.observer/filing/0001193125-24-071467.txt

## Key facts
- Executive change
  Patrik Jeanmonod changed role as Chief Financial Officer at Cytek Biosciences, Inc..
  - Action: stepped down
  - Role: Chief Financial Officer
  source text: Effective as of March 17, 2024, Patrik Jeanmonod stepped down from his position as the Chief Financial Officer of Cytek Biosciences, Inc. (the “Company”) to serve as the Company’s Head of Corporate Development Analytics.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312524071467/0001193125-24-071467-index.htm
- Executive change
  William McCombe was appointed as Chief Financial Officer at Cytek Biosciences, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On March 19, 2024, the Board of Directors of the Company announced the appointment of William (“Bill”) McCombe as the Chief Financial Officer of the Company, effective March 18, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312524071467/0001193125-24-071467-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.